Veracyte Inc
NASDAQ:VCYT
Veracyte Inc
Cost of Revenue
Veracyte Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Veracyte Inc
NASDAQ:VCYT
|
Cost of Revenue
-$112.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-25%
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-27%
|
See Also
What is Veracyte Inc's Cost of Revenue?
Cost of Revenue
-112.9m
USD
Based on the financial report for Dec 31, 2023, Veracyte Inc's Cost of Revenue amounts to -112.9m USD.
What is Veracyte Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-25%
Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for Veracyte Inc have been -40% over the past three years , -28% over the past five years , and -25% over the past ten years .